| 2026-07-16 | Press release | Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million |
| 2026-06-15 | Press release | Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma |
| 2026-05-08 | Press release | Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC |
| 2026-04-21 | Press release | Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer |
| 2026-04-20 | Press release | Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer |
| 2026-03-02 | Press release | Inhibrx Announces Participation in Upcoming Scientific Conference |
| 2025-12-16 | Press release | Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX |
| 2025-11-04 | Press release | Inhibrx Announces Participation in Upcoming Scientific Conferences |
| 2025-10-23 | Press release | Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosa |
| 2025-10-22 | Press release | Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondr |
| 2025-04-01 | Press release | Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President |
| 2025-01-21 | Press release | Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colo |
| 2025-01-13 | Press release | Inhibrx Biosciences Announces Loan Agreement with Oxford Finance |
| 2024-11-04 | Press release | Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation |
| 2024-05-24 | Press release | Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi |
| 2024-05-10 | Press release | Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off |
| 2024-05-08 | Press release | Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effe |
| 2024-01-23 | Press release | Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B |
| 2023-11-02 | Press release | Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma |
| 2023-10-18 | Press release | Inhibrx Announces Participation in Upcoming Scientific Conferences |
| 2023-08-29 | Press release | Inhibrx Announces $200 Million Private Placement Financing |
| 2023-04-26 | Press release | Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBR |